Janssen extends Blue Latitude contract for Strategic Marketing Services to the EMEA region

Following a successful partnership, Janssen has reappointed Blue Latitude to provide strategic marketing support and services to the company's brand teams in the EMEA region

LONDON, 16th September 2015 – Blue Latitude, a strategic marketing consultancy specialising in healthcare, announced todaythat it has been reappointed to provide Janssen with strategic support and creative marketing services for their brand teams in the EMEA region.

Blue Latitude has delivered innovative strategic marketing solutions to the pharmaceutical and healthcare industry over the last 12 years with a particular emphasis on strategy, customer experience and creative services. Following this renewedthree year contract, Blue Latitude will continue its successful partnership with Janssen with its fullbreadth of services across a wide range of therapy areas.

Wayne Atherden, Procurement Director Commercial Services at Janssen, said, "This new strategic relationship is an extension of our already successful partnership with Blue Latitude as they have demonstrated a solid knowledge of our marketing needs alongside strong strategic thinking, energy and creativity. We very much look forward to continuing to work with Blue Latitude to take our marketing strategy to the next level."
Martin Brass, Blue Latitude's Co-founder and Managing Director, said: "We are absolutely thrilled to extend our partnership with Janssen to include theirbrand teams in the EMEA region and start offering our full range of strategic marketing services.
"At Blue Latitude, we work with clients to provide answers and give marketers confidence to undertake multichannel and creative solutions that truly change behaviour and optimise performance."

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?